Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 2
2005 4
2006 3
2007 5
2008 3
2009 2
2010 4
2011 2
2012 3
2013 4
2014 2
2015 3
2016 2
2019 5
2020 3
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients.
Beltrán-Visiedo M, Jiménez-Alduán N, Díez R, Cuenca M, Benedi A, Serrano-Del Valle A, Azaceta G, Palomera L, Peperzak V, Anel A, Naval J, Marzo I. Beltrán-Visiedo M, et al. Among authors: naval j. Mol Oncol. 2023 Dec;17(12):2507-2525. doi: 10.1002/1878-0261.13522. Epub 2023 Sep 28. Mol Oncol. 2023. PMID: 37704591 Free PMC article.
Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.
Serrano Del Valle A, Beltrán-Visiedo M, de Poo-Rodríguez V, Jiménez-Alduán N, Azaceta G, Díez R, Martínez-Lázaro B, Izquierdo I, Palomera L, Naval J, Anel A, Marzo I. Serrano Del Valle A, et al. Among authors: naval j. Oncoimmunology. 2022 Nov 1;11(1):2141973. doi: 10.1080/2162402X.2022.2141973. eCollection 2022. Oncoimmunology. 2022. PMID: 36338146 Free PMC article.
Future prospects for mitosis-targeted antitumor therapies.
Serrano-Del Valle A, Reina-Ortiz C, Benedi A, Anel A, Naval J, Marzo I. Serrano-Del Valle A, et al. Among authors: naval j. Biochem Pharmacol. 2021 Aug;190:114655. doi: 10.1016/j.bcp.2021.114655. Epub 2021 Jun 12. Biochem Pharmacol. 2021. PMID: 34129859 Free article. Review.
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.
Reina-Ortiz C, Constantinides M, Fayd-Herbe-de-Maudave A, Présumey J, Hernandez J, Cartron G, Giraldos D, Díez R, Izquierdo I, Azaceta G, Palomera L, Marzo I, Naval J, Anel A, Villalba M. Reina-Ortiz C, et al. Among authors: naval j. Oncoimmunology. 2020 Dec 29;10(1):1853314. doi: 10.1080/2162402X.2020.1853314. Oncoimmunology. 2020. PMID: 33457074 Free PMC article.
Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.
Calvo T, Reina-Ortiz C, Giraldos D, Gascón M, Woods D, Asenjo J, Marco-Brualla J, Azaceta G, Izquierdo I, Palomera L, Sánchez-Martínez D, Marzo I, Naval J, Vilches C, Villalba M, Anel A. Calvo T, et al. Among authors: naval j. Sci Rep. 2020 Nov 10;10(1):19398. doi: 10.1038/s41598-020-76051-z. Sci Rep. 2020. PMID: 33173077 Free PMC article.
Novel Forms of Immunomodulation for Cancer Therapy.
Serrano-Del Valle A, Naval J, Anel A, Marzo I. Serrano-Del Valle A, et al. Among authors: naval j. Trends Cancer. 2020 Jun;6(6):518-532. doi: 10.1016/j.trecan.2020.02.015. Epub 2020 Mar 31. Trends Cancer. 2020. PMID: 32460005 Review.
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma.
Serrano-Del Valle A, Anel A, Naval J, Marzo I. Serrano-Del Valle A, et al. Among authors: naval j. Front Cell Dev Biol. 2019 Apr 16;7:50. doi: 10.3389/fcell.2019.00050. eCollection 2019. Front Cell Dev Biol. 2019. PMID: 31041312 Free PMC article. Review.
48 results